Treatment recommendations for the various subgroups of neurocytomas

Dirk Rades, Steven E. Schild

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Neurocytomas gained importance since 1995, which is reflected by the increasing number of reports on this entity. This study was performed to determine the best available treatment for typical and atypical neurocytomas (MIB-1 labeling index > 3%, atypical histology) in various age groups (≤18 years, >18 years). The data of all neurocytoma patients reported since 1982, when this entity were reviewed for age, gender, extent of resection, MIB-1 labeling index, histology, radiotherapy, and outcome of therapy. Patients were treated with complete resection alone (CTR), CTR plus radiotherapy (CTR + RT), incomplete resection alone (ITR), or ITR plus radiotherapy (ITR + RT). If the reported data were incomplete, the authors were contacted for additional data. Follow up had to be at least 12 months. Data were complete in 438 patients (73 children, 365 adults). Three hundred and fifty-one patients had typical, 87 atypical lesions. Typical lesions were associated with better local control and survival than atypical lesions (P < 0.001). CTR was superior to ITR (P < 0.001). After CTR, outcome was not significantly improved by RT. After ITR, RT improved survival in typical lesions (P = 0.03) and atypical lesions (P = 0.05), not in children (P = 0.16). Local control was improved in all groups (P < 0.001, children P = 0.01). Doses >54 Gy appeared beneficial after ITR of atypical lesions. In children, ≤50 Gy and >50 Gy were comparable. CTR does not require post-operative RT. Following ITR, RT improves outcome. Of 50-54 Gy appear sufficient for typical lesions, 50 Gy for children. Atypical lesions require 56-60 Gy.

Original languageEnglish (US)
Pages (from-to)305-309
Number of pages5
JournalJournal of Neuro-Oncology
Volume77
Issue number3
DOIs
StatePublished - May 2006

Fingerprint

Neurocytoma
Radiotherapy
Histology
Therapeutics
Age Groups
Survival

Keywords

  • Neurocytoma subgroups
  • Radiotherapy
  • Surgery
  • Treatment recommendations

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Treatment recommendations for the various subgroups of neurocytomas. / Rades, Dirk; Schild, Steven E.

In: Journal of Neuro-Oncology, Vol. 77, No. 3, 05.2006, p. 305-309.

Research output: Contribution to journalArticle

Rades, Dirk ; Schild, Steven E. / Treatment recommendations for the various subgroups of neurocytomas. In: Journal of Neuro-Oncology. 2006 ; Vol. 77, No. 3. pp. 305-309.
@article{87bc9c9813204c57be17741674baddd5,
title = "Treatment recommendations for the various subgroups of neurocytomas",
abstract = "Neurocytomas gained importance since 1995, which is reflected by the increasing number of reports on this entity. This study was performed to determine the best available treatment for typical and atypical neurocytomas (MIB-1 labeling index > 3{\%}, atypical histology) in various age groups (≤18 years, >18 years). The data of all neurocytoma patients reported since 1982, when this entity were reviewed for age, gender, extent of resection, MIB-1 labeling index, histology, radiotherapy, and outcome of therapy. Patients were treated with complete resection alone (CTR), CTR plus radiotherapy (CTR + RT), incomplete resection alone (ITR), or ITR plus radiotherapy (ITR + RT). If the reported data were incomplete, the authors were contacted for additional data. Follow up had to be at least 12 months. Data were complete in 438 patients (73 children, 365 adults). Three hundred and fifty-one patients had typical, 87 atypical lesions. Typical lesions were associated with better local control and survival than atypical lesions (P < 0.001). CTR was superior to ITR (P < 0.001). After CTR, outcome was not significantly improved by RT. After ITR, RT improved survival in typical lesions (P = 0.03) and atypical lesions (P = 0.05), not in children (P = 0.16). Local control was improved in all groups (P < 0.001, children P = 0.01). Doses >54 Gy appeared beneficial after ITR of atypical lesions. In children, ≤50 Gy and >50 Gy were comparable. CTR does not require post-operative RT. Following ITR, RT improves outcome. Of 50-54 Gy appear sufficient for typical lesions, 50 Gy for children. Atypical lesions require 56-60 Gy.",
keywords = "Neurocytoma subgroups, Radiotherapy, Surgery, Treatment recommendations",
author = "Dirk Rades and Schild, {Steven E.}",
year = "2006",
month = "5",
doi = "10.1007/s11060-005-9047-3",
language = "English (US)",
volume = "77",
pages = "305--309",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Treatment recommendations for the various subgroups of neurocytomas

AU - Rades, Dirk

AU - Schild, Steven E.

PY - 2006/5

Y1 - 2006/5

N2 - Neurocytomas gained importance since 1995, which is reflected by the increasing number of reports on this entity. This study was performed to determine the best available treatment for typical and atypical neurocytomas (MIB-1 labeling index > 3%, atypical histology) in various age groups (≤18 years, >18 years). The data of all neurocytoma patients reported since 1982, when this entity were reviewed for age, gender, extent of resection, MIB-1 labeling index, histology, radiotherapy, and outcome of therapy. Patients were treated with complete resection alone (CTR), CTR plus radiotherapy (CTR + RT), incomplete resection alone (ITR), or ITR plus radiotherapy (ITR + RT). If the reported data were incomplete, the authors were contacted for additional data. Follow up had to be at least 12 months. Data were complete in 438 patients (73 children, 365 adults). Three hundred and fifty-one patients had typical, 87 atypical lesions. Typical lesions were associated with better local control and survival than atypical lesions (P < 0.001). CTR was superior to ITR (P < 0.001). After CTR, outcome was not significantly improved by RT. After ITR, RT improved survival in typical lesions (P = 0.03) and atypical lesions (P = 0.05), not in children (P = 0.16). Local control was improved in all groups (P < 0.001, children P = 0.01). Doses >54 Gy appeared beneficial after ITR of atypical lesions. In children, ≤50 Gy and >50 Gy were comparable. CTR does not require post-operative RT. Following ITR, RT improves outcome. Of 50-54 Gy appear sufficient for typical lesions, 50 Gy for children. Atypical lesions require 56-60 Gy.

AB - Neurocytomas gained importance since 1995, which is reflected by the increasing number of reports on this entity. This study was performed to determine the best available treatment for typical and atypical neurocytomas (MIB-1 labeling index > 3%, atypical histology) in various age groups (≤18 years, >18 years). The data of all neurocytoma patients reported since 1982, when this entity were reviewed for age, gender, extent of resection, MIB-1 labeling index, histology, radiotherapy, and outcome of therapy. Patients were treated with complete resection alone (CTR), CTR plus radiotherapy (CTR + RT), incomplete resection alone (ITR), or ITR plus radiotherapy (ITR + RT). If the reported data were incomplete, the authors were contacted for additional data. Follow up had to be at least 12 months. Data were complete in 438 patients (73 children, 365 adults). Three hundred and fifty-one patients had typical, 87 atypical lesions. Typical lesions were associated with better local control and survival than atypical lesions (P < 0.001). CTR was superior to ITR (P < 0.001). After CTR, outcome was not significantly improved by RT. After ITR, RT improved survival in typical lesions (P = 0.03) and atypical lesions (P = 0.05), not in children (P = 0.16). Local control was improved in all groups (P < 0.001, children P = 0.01). Doses >54 Gy appeared beneficial after ITR of atypical lesions. In children, ≤50 Gy and >50 Gy were comparable. CTR does not require post-operative RT. Following ITR, RT improves outcome. Of 50-54 Gy appear sufficient for typical lesions, 50 Gy for children. Atypical lesions require 56-60 Gy.

KW - Neurocytoma subgroups

KW - Radiotherapy

KW - Surgery

KW - Treatment recommendations

UR - http://www.scopus.com/inward/record.url?scp=33748437123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748437123&partnerID=8YFLogxK

U2 - 10.1007/s11060-005-9047-3

DO - 10.1007/s11060-005-9047-3

M3 - Article

VL - 77

SP - 305

EP - 309

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -